Eiger BioPharmaceuticals Operating Income

Eiger BioPharmaceuticals posts a operating income of $-72M as of December 2023. That compares with $-93M in the prior-year period — up 22.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Eiger BioPharmaceuticals's operating income was $-93M. The latest reading is $-72M — a 22.6% year-over-year increase (period ending December 2023). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Eiger BioPharmaceuticals's financial statement story. At $-72M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for EIGR's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Eiger BioPharmaceuticals's other metric pages and overview cover the third.

Judging Eiger BioPharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in operating income easier to interpret. Start with $-72M here, then scan peer and history charts to see if the gap is persistent.